Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlookCOPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook.
12M 2024: Novonesis delivers strong full-year results and expects continued growth in 2025Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin of 36.1% in 2024. For 2025, Novonesis presents an outlook of 5-8% organic sales growth with an adjusted EBITDA margin of 37-38%.
Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme AllianceNovonesis has reached an agreement with dsm-firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities, in exchange for a total cash consideration of EUR 1.5 billion. After more than 25 years of successful collaboration, a strategic repositioning at dsm-firmenich allowed this opportunity to materialize. This acquisition is aligned with Novonesis’ growth strategy and expands its presence across the animal biosolutions value chain. Financially, this transaction is accretive to revenue growth, adjusted EBITDA margin and adjusted EPS excl. amortization, with attractive revenue synergies.
Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8%Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%.
